AKTX

Akari Therapeutics Plc ADR

8.18

Oct 16 • 3:59 PM ET -0.66 (-7.47%)

8.51

Aftermarket • 4:15 PM ET +0.33 (4.03%)

Healthcare Biotechnology USA Nano NASD

Oct 15, 9:55 AMAkari starts IND-enabling studies, large-scale GMP manufacturing for lead ADC AKTX-101, targets first-in-human Phase 1 trial by mid-2027

Peers: IKT NBP NERV NVCT ALXO BCYC CGEN FATE FHTX CDXS

Scroll to Statements

Index	-
Market Cap	14.32M
Enterprise Value	7.26M
Income	-30.90M
Sales	0.00M
Book/sh	10.62
Cash/sh	4.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	May 07, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.77
P/C	1.85
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.60
Current Ratio	0.60
Debt/Eq	0.04
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-17.25
EPS next Y	-5.49
EPS next Q	-2.23
EPS this Y	52.32%
EPS next Y	44.32%
EPS next 5Y	46.65%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	1.39%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	100.00% -

Insider Own	0.40%
Insider Trans	0.00%
Inst Own	8.71%
Inst Trans	243.35%
ROA	-69.02%
ROE	-139.80%
ROIC	-166.16%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.55%
SMA50	-9.79%
SMA200	-11.07%
Trades

Shs Outstand	1.75M
Shs Float	1.74M
Short Float	0.83%
Short Ratio	0.24
Short Interest	0.01M
52W High	33.60 -75.65%
52W Low	3.02 171.31%
Volatility	13.39% 11.59%
ATR (14)	1.03
RSI (14)	44.27
Beta	1.46
Rel Volume	0.35
Avg Volume	61.36K
Volume	21,689

Perf Week	-6.73%
Perf Month	-17.16%
Perf Quarter	-23.26%
Perf Half Y	41.03%
Perf YTD	-29.24%
Perf Year	-73.44%
Perf 3Y	-94.07%
Perf 5Y	-99.38%
Perf 10Y	-99.88%
Recom	1.00
Target Price	25.50
Prev Close	8.84
Price	8.18
Change %	-7.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-26	Upgrade	Maxim Group	Hold → Buy	$30
Apr-08-26	Downgrade	Maxim Group	Buy → Hold
Jan-05-26	Initiated	Ladenburg Thalmann	Buy	$1
Jul-18-25	Initiated	Maxim Group	Buy	$5
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy	$2.50 → $3
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral	$3
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral	$6
Apr-17-17	Reiterated	Chardan Capital Markets	Sell	$6.50 → $5
Jul-11-16	Initiated	Chardan Capital Markets	Sell	$5

Oct-15-26 09:20AM	Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner (GlobeNewswire) +21.43%
Oct-13-26 09:01AM	Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering (GlobeNewswire) -7.49%
Oct-01-26 08:25AM	Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers (GlobeNewswire)
Sep-08-26 09:15AM	Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums (GlobeNewswire)
Aug-27-26 09:01AM	Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference (GlobeNewswire)
08:53AM	Loading…
Aug-18-26 08:53AM	Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy (GlobeNewswire) +5.04%
Aug-13-26 04:15PM	Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform (GlobeNewswire) +7.71%
Aug-04-26 08:50AM	Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation (GlobeNewswire) +5.84%
Jul-22-26 08:40AM	Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity (GlobeNewswire) +5.54%
Jul-21-26 07:05AM	Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics (GlobeNewswire) -12.80%
Jul-07-26 08:55AM	Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board (GlobeNewswire) +42.02%
Jun-29-26 08:45AM	Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones (GlobeNewswire) -9.69%
Jun-04-26 09:30AM	Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026 (GlobeNewswire) +5.71%
May-28-26 06:33PM	Akari Therapeutics Highlights 1st ASCO Abstract Acceptance (IPO-Edge.com) +38.46% -25.49%
09:17AM	Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor "What This Means" Segment Following ASCO Abstract Acceptance (GlobeNewswire)
05:01PM	Loading…
May-21-26 05:01PM	Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models (GlobeNewswire) +49.85% +255.45%
08:30AM	Akari Therapeutics Announces $5.5 Million Private Placement Offering (GlobeNewswire)
May-18-26 09:05AM	Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase (GlobeNewswire)
May-12-26 08:33AM	Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets (GlobeNewswire) -40.58%
Apr-27-26 08:35AM	Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload (GlobeNewswire)
Apr-21-26 09:00AM	Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors (GlobeNewswire)
Apr-20-26 08:35AM	Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing (GlobeNewswire)
Apr-09-26 08:50AM	Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC (GlobeNewswire)
Apr-06-26 08:45AM	Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing (GlobeNewswire) -20.81%
Mar-18-26 08:05AM	Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 (GlobeNewswire) -24.72%
Mar-17-26 04:30PM	Akari Therapeutics Announces ADS Ratio Change (GlobeNewswire)
Mar-13-26 09:15AM	Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala (GlobeNewswire) -10.71%
Feb-26-26 09:10AM	Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board (GlobeNewswire)
Feb-23-26 08:50AM	Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board (GlobeNewswire)
Feb-18-26 09:05AM	Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference (GlobeNewswire)
08:45AM	Loading…
Feb-11-26 08:45AM	Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing the Company's Expanded ADC Pipeline (GlobeNewswire)
Feb-05-26 09:15AM	Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire)
Jan-26-26 08:45AM	Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors (GlobeNewswire)
Jan-17-26 07:00AM	MarketBeat Week in Review - 01/12 - 01/16 (MarketBeat)
Jan-09-26 09:00AM	Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 (GlobeNewswire)
Jan-08-26 09:15AM	Akari Therapeutics to Present at the 2026 Biotech Showcase (GlobeNewswire)
Dec-30-25 09:15AM	Akari Therapeutics Issues 2025 End of Year Letter to Shareholders (GlobeNewswire)
Dec-23-25 08:30AM	Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial (GlobeNewswire) -7.08%
Dec-18-25 08:30AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Dec-16-25 09:29AM	Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market (GlobeNewswire) -38.30%
Dec-09-25 08:40AM	Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer (GlobeNewswire)
Dec-04-25 09:00AM	Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment (GlobeNewswire)
Nov-25-25 09:00AM	Akari Therapeutics Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Nov-18-25 08:35AM	Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer (GlobeNewswire) +12.04%
Nov-10-25 08:30AM	Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors (GlobeNewswire)
Nov-04-25 09:25AM	Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available (GlobeNewswire) +13.10%
Oct-30-25 08:35AM	Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP (GlobeNewswire)
Oct-22-25 09:05AM	Akari Therapeutics Announces Launch of CEO Corner Platform (GlobeNewswire)
Oct-15-25 08:30AM	Akari Therapeutics Announces $2.5 Million Registered Direct Offering (GlobeNewswire) -16.34%
Oct-10-25 08:50AM	Akari Therapeutics files two new patents with USPTO (TipRanks) -8.82%
Oct-09-25 08:45AM	Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 (GlobeNewswire)
Oct-03-25 09:30AM	Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire)
Sep-24-25 08:45AM	Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 (GlobeNewswire) +45.96%
Sep-17-25 08:45AM	Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer (GlobeNewswire) +5.11%
Sep-05-25 06:45AM	Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +12.15%
Sep-03-25 08:30AM	Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -6.42%
Aug-14-25 09:15AM	Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Jul-29-25 09:15AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Jul-23-25 08:55AM	Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers (GlobeNewswire)
Jul-22-25 08:45AM	Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jun-25-25 09:00AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent (GlobeNewswire)
Jun-18-25 08:50AM	Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India (GlobeNewswire)
May-29-25 09:15AM	Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology (GlobeNewswire)
May-22-25 09:00AM	Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire)
May-15-25 08:05AM	Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-25 08:45AM	Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology (GlobeNewswire)
Apr-22-25 09:05AM	Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala (GlobeNewswire) +6.25%
Apr-16-25 08:00AM	Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.24%
Mar-20-25 08:44AM	Akari Therapeutics appoints Abizer Gaslightwala as CEO (SeekingAlpha) +20.00%
08:35AM	Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer (GlobeNewswire)
Mar-03-25 09:00AM	Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules (GlobeNewswire) +7.70%
Feb-19-25 09:00AM	Akari Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire) +5.30%
Feb-03-25 08:00AM	Akari Therapeutics Joins Webull Corporate Connect Service Platform (GlobeNewswire) +9.17%
Dec-18-24 08:51AM	Akari Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
Dec-16-24 09:05AM	Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer (GlobeNewswire)
Nov-19-24 08:00AM	Akari Therapeutics Regains Full Nasdaq Compliance (GlobeNewswire) -31.44%
Nov-14-24 04:15PM	Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio (GlobeNewswire) -6.73%
Nov-08-24 08:00AM	Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger (GlobeNewswire)
Oct-15-24 08:00AM	Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger (GlobeNewswire)
Sep-17-24 08:00AM	Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics (GlobeNewswire)
Aug-19-24 04:15PM	Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) +5.42%
08:00AM	Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy (GlobeNewswire)
Jun-05-24 08:00AM	Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders (GlobeNewswire) +9.88%
Jun-04-24 08:00AM	Akari Therapeutics Secures $7.6 Million in Upsized Financing Round (GlobeNewswire) +14.20%
May-16-24 08:00AM	Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
May-01-24 08:01AM	Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics (GlobeNewswire) +10.39%
08:00AM	Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity (GlobeNewswire)
Apr-15-24 08:00AM	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 (GlobeNewswire)
Apr-01-24 06:30AM	Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights (GlobeNewswire) -19.03%
Mar-08-24 04:38PM	Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm (GlobeNewswire)
Mar-05-24 08:00AM	Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire)
Jan-02-24 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing (GlobeNewswire) -7.16%
Dec-14-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2024 (GlobeNewswire) +5.84%
Dec-01-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors (GlobeNewswire) +9.49%
Nov-16-23 08:00AM	Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Nov-06-23 08:00AM	Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.21%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire) +6.30%

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

CEOMr. Abizer Gaslightwala

Executive Director & Head of OncologyDr. Satyajit Mitra Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Sandip I	Director	Oct 14 '26	Option Exercise	0.00	10,052	4	38,877	Oct 16 05:20 PM
Bazemore Robert B	Director	Oct 14 '26	Option Exercise	0.00	3,866	2	22,759	Oct 16 05:20 PM
Gaslightwala Abizer	CEO	Oct 14 '26	Option Exercise	0.00	27,066	11	41,173	Oct 16 05:20 PM
Patel Samir Rashmikant	Director	Jul 07 '26	Option Exercise	0.43	22,474	9,681	98,241	Jul 17 06:03 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKTX

Akari Therapeutics Plc ADR

Upgrade your Finviz experience